证券代码：688670证券简称：金迪克公告编号：2026-001 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 1、公司预计2025年度实现归属于母公司所有者的净利润为-18,000.00万元到-16,000.00万元，将出现亏 损，与上年同期相比，亏损增加6,649.72万元到8,649.72万元，同比增亏71.12%到92.51%。 2、公司预计2025年度归属于母公司所有者扣除非经常性损益后的净利润为-18,500.00万元到-16,500.00 万元，与上年同期相比，亏损增加5,877.65万元到7,877.65万元，同比增亏55.33%到74.16%。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况 2024年度，公司实现利润总额-11,574.95万元，归属于母公司所有者的净利润为-9,350.28万元，归属于 母公司所有者的扣除非经常性损益的净利润为-10,622.35万元，基本每股收益-0.76元/股，稀释每股收 益-0.76元/股。 三 ...

报告期内，因设备故障、耗材批间差异等原因使部分在产品和产成品存在风险，本着谨慎的原则，公司 决定将该部分在产品和产成品不再进行上市销售；同时，公司四价流感病毒裂解疫苗有效期为自生产之 日起12个月，在每一流感季末，近效期未实现接种的流感疫苗需要按照有关法律法规要求进行报废销毁 处理。针对已销售未接种的流感疫苗，经客户申请公司审批后，可以办理退回。公司根据市场调研情 况，结合历史退货率等情况，对期后可能发生退货的产品计提了资产减值准备。全年计提资产减值准备 及存货报废处置合计约4,199.96万元（最终以2025年年度报告数据为准）。 报告期内，公司四价流感病毒裂解疫苗（儿童）项目Ⅲ期临床试验受试者已全部完成入组，并完成了疫 苗的接种工作，目前血清正在中检院进行检验。同时，公司三价流感病毒裂解疫苗提交上市生产的申请 已受理，同步完成了注册检验、标准复核、注册现场核查和GMP符合性检查，目前等待CDE的进一步 审评。上述四价流感病毒裂解疫苗（儿童）项目以及三价流感病毒裂解疫苗项目投入增加导致公司研发 投入同比大幅增加，对本报告期利润造成一定影响。 格隆汇1月30日丨金迪克(688670.SH)公布，经财务部初步测 ...

南财智讯1月30日电，金迪克发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为-1.60 亿元—-1.80亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-1.65亿元 —-1.85亿元。归属于上市公司股东的净利润同比增亏71.12%—92.51%。本期业绩变化的主要原因：报 告期内，公司提前排产，加强设备维护维修与车间环境保持，狠抓劳动纪律，提升生产效率，各部门协 调配合，加快流感疫苗生产和批签发节奏，出货时间较上年有所提前，2025年实现销售收入约11,200万 元，较上年有一定幅度增长。但基于以下原因，公司仍然处于亏损状态：1、报告期内，公司四价流感 病毒裂解疫苗（儿童）项目III期临床试验受试者已全部完成入组，并完成了疫苗的接种工作，目前血清 正在中检院进行检验。同时，公司三价流感病毒裂解疫苗提交上市生产的申请已受理，同步完成了注册 检验、标准复核、注册现场核查和GMP符合性检查，目前等待CDE的进一步审评。上述四价流感病毒 裂解疫苗（儿童）项目以及三价流感病毒裂解疫苗项目投入增加导致公司研发投入同比大幅增加，对本 报告期利润造成一定影响。2、报告期内，因设备故障、 ...

Core Viewpoint - Fosun Pharma is seeking new growth opportunities in the vaccine sector through the spin-off and listing of its vaccine platform, Fosun Antigen, on the Hong Kong Stock Exchange, which is seen as a strategic move to support independent development and capitalize on the revaluation of quality assets in the market [2][10]. Group 1: Spin-off and Financials - The spin-off plan announced on January 22 involves an initial issuance not exceeding 25% of the expanded total share capital of Fosun Antigen, which will remain a subsidiary of Fosun Pharma, reflecting its financial status in the consolidated financial statements [2][3]. - Fosun Antigen's projected revenues for 2022, 2023, and 2024 are 460 million yuan, 340 million yuan, and 97.42 million yuan respectively, with net profits of 86.64 million yuan, 11.35 million yuan, and a loss of 123.39 million yuan in 2024 [3][4]. Group 2: Market Potential and Competition - The global vaccine market is experiencing rapid expansion, with a size of $77 billion in 2023 and a compound annual growth rate (CAGR) of 15% from 2019 to 2023. The Chinese vaccine market (excluding COVID-19 vaccines) is expected to reach approximately 101.77 billion yuan in 2024, growing to 300 billion yuan by 2035, with an annual growth rate of about 12% [4][5]. - The Chinese vaccine market has significant growth potential, particularly in rabies and influenza vaccines, where current vaccination rates are low, indicating room for increased demand [5][6]. Group 3: Competitive Advantages and Challenges - Fosun Antigen has established a diverse range of vaccine products, including rabies and influenza vaccines, and is developing high-end products like the 13-valent pneumococcal conjugate vaccine, which is currently in Phase III clinical trials [6][7]. - The domestic vaccine market is characterized by moderate competition compared to the pharmaceutical market, with over 40 vaccine manufacturers. The focus is on collaboration to enhance market size and vaccination rates rather than engaging in cutthroat competition [5][8]. Group 4: Future Outlook - The spin-off of Fosun Antigen is part of Fosun Pharma's broader strategy to optimize asset structure and unlock the value of its subsidiaries, with previous successful spin-offs providing a framework for this move [10][11]. - The future of the vaccine market is expected to be competitive, especially in the pneumococcal vaccine sector, where established players like Pfizer dominate. The rapid development of mRNA vaccine technology poses additional challenges for traditional vaccine companies [10][11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600196 股票简称：复星医药 编号：临2026-009 上海复星医药（集团）股份有限公司 关于分拆子公司上市的 一般风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2026年1月22日，上海复星医药（集团）股份有限公司（以下简称"本公司"）召开第十届董事会第二十 二次会议，会议审议通过拟分拆所属子公司复星安特金（成都）生物制药股份有限公司（以下简称"复 星安特金"）至香港联合交易所有限公司（以下简称"香港联交所"）主板上市（以下简称"本次分拆上 市"或"本次分拆"）的相关议案。本次分拆完成后，预计不会影响本公司对复星安特金的控制权。详情 请见同日刊登于《中国证券报》《上海证券报》《证券时报》和上海证券交易所网站 （https://www.sse.com.cn）的相关公告。 本次分拆的相关风险提示如下： 证券代码：600196 股票简称：复星医药 编号：临2026-008 上海复星医药（集团）股份有限公司 第十届董事会第二十二次会议 （临时会议）决议 ...

Core Viewpoint - Fosun Pharma is planning to spin off its subsidiary, Fosun Antigen, for a listing on the Hong Kong Stock Exchange amid fluctuating performance and increasing debt levels [2][4]. Financial Performance - For the first three quarters of 2025, Fosun Pharma reported a revenue of 29.393 billion yuan, a decrease of 4.91% year-on-year, while net profit increased by 25.50% to 2.523 billion yuan [12]. - In 2023, Fosun Pharma's revenue was 41.4 billion yuan, down 5.81% year-on-year, and net profit fell by 36.04% to 2.386 billion yuan [11]. - The company has experienced a decline in revenue over the past few years, with 2022 revenue at 43.952 billion yuan, a 12.66% increase, but net profit decreased by 21.10% [9]. Debt and Cash Flow - As of the end of Q3 2025, Fosun Pharma had cash and cash equivalents of 11.478 billion yuan and short-term borrowings of 16.447 billion yuan, indicating tight cash flow [12]. - Fosun Antigen's debt ratio increased from 33.87% at the end of 2024 to 43.72% by mid-2025, reflecting a rise of approximately 10 percentage points in just six months [7]. Spin-off Details - The spin-off of Fosun Antigen aims to enhance its governance and sustainable development, thereby maximizing shareholder value [4]. - Fosun Antigen focuses on the research, production, and sales of human vaccines and has developed several vaccines that have been approved for sale in China [6]. Investment Initiatives - Fosun Pharma's subsidiary plans to establish a target fund with a total fundraising goal of 1 billion yuan, with Fosun Pharma contributing 100 million yuan [13]. - The fund aims to leverage partnerships with various investors to expand in innovative drugs, biopharmaceuticals, and high-end medical devices [13].

Core Viewpoint - Fosun Pharma is planning to spin off its subsidiary, Fosun Antigen, for a listing on the Hong Kong Stock Exchange amid fluctuating performance and financial challenges [2][3]. Financial Performance - For the first three quarters of 2025, Fosun Pharma reported a revenue of 29.393 billion yuan, a year-on-year decrease of 4.91%, while net profit increased by 25.50% to 2.523 billion yuan [9]. - The company has experienced a decline in revenue over the past few years, with 2023 revenue at 41.4 billion yuan, down 5.81% year-on-year, and net profit dropping 36.04% to 2.386 billion yuan [9]. - As of the end of the third quarter of 2025, Fosun Pharma's cash and cash equivalents amounted to 11.478 billion yuan, with short-term borrowings at 16.447 billion yuan and long-term borrowings at 9.431 billion yuan, indicating tight cash flow [9]. Subsidiary Performance - Fosun Antigen has accumulated a net loss of 182 million yuan over the past year and a half, with its debt ratio increasing from 33.87% at the end of 2024 to 43.72% by mid-2025, a rise of approximately 10 percentage points [5]. - As of June 30, 2025, Fosun Antigen's total assets were 3.972 billion yuan, with total liabilities of 1.737 billion yuan [4]. Spin-off Strategy - The proposed spin-off aims to enhance Fosun Antigen's financing channels and market competitiveness, while also deepening Fosun Pharma's presence in the vaccine sector [3][4]. - Fosun Antigen focuses on the research, production, and sales of human vaccines, with several products already approved for sale in China [4]. Investment Activities - Fosun Pharma plans to establish a target fund with a total fundraising goal of 1 billion yuan, with the company contributing 100 million yuan [10]. - The fund aims to leverage partnerships with various investors to expand Fosun Pharma's presence in innovative drugs, biopharmaceuticals, and high-end medical devices [10].

Core Viewpoint - Domestic biopharmaceutical companies are increasingly pursuing listings in Hong Kong, with Fosun Pharma planning to spin off its vaccine business, Fosun Antigen, for a Hong Kong listing, while maintaining control over it [1][2]. Company Summary - Fosun Antigen, established in July 2012, focuses on the research, production, and sales of human vaccines, having developed both bacterial and viral vaccine technology platforms [1]. - Fosun Pharma holds approximately 70.08% of Fosun Antigen's shares through its subsidiary, Shanghai Fosun Pharma Industry Development Co., Ltd. [1]. - Fosun Antigen has received approval for several vaccines in China, including rabies vaccines and influenza vaccines, while its 13-valent pneumococcal conjugate vaccine is in Phase III clinical trials [1]. Financial Performance - Fosun Antigen reported a revenue of 153 million yuan and a net loss of 58.45 million yuan in the first half of the year [2]. Strategic Implications - The spin-off is expected to enhance Fosun Antigen's financing channels and market competitiveness, while also allowing Fosun Pharma to deepen its presence in the vaccine sector [2]. - The trend of A-share listed pharmaceutical companies pursuing dual listings in Hong Kong is gaining momentum, driven by the need to expand overseas and attract international investors [3]. Market Context - Hong Kong's market offers diverse international investors and improved liquidity, making it an attractive option for companies like Fosun Pharma to list their subsidiaries [3]. - The successful listings of companies such as Hengrui Medicine and others have created a demonstrative effect, encouraging more firms to consider Hong Kong as a viable listing destination [3].

Core Viewpoint - The company Fosun Pharma plans to spin off its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange to enhance governance and sustainable development, thereby maximizing shareholder value [1][2]. Group 1: Company Overview - Fosun Antigen was established in July 2012 and focuses on the research, production, and sales of human vaccines, having developed platforms for both bacterial and viral vaccines [1]. - As of the announcement date, Fosun Pharma's subsidiary Shanghai Fosun Pharma Industry Development Co., Ltd. holds approximately 70.08% of Fosun Antigen, while 17 other shareholders collectively own about 29.92% [2]. Group 2: Financial Performance - Fosun Antigen reported revenues of 97.42 million yuan and a net loss of 123 million yuan for 2024. For the first half of 2025, it achieved revenues of 153 million yuan with a net loss of 58.45 million yuan [2]. - Fosun Pharma's Q3 2025 report indicated total revenues of 29.393 billion yuan, a year-on-year decrease of 4.91%, while net profit attributable to shareholders was 2.523 billion yuan, reflecting a year-on-year increase of 25.5% [2]. Group 3: Market Context - The trend of A-share pharmaceutical companies planning to list in Hong Kong is gaining momentum, driven by favorable policies, market recovery, and the international platform advantages of the Hong Kong Stock Exchange [3].

Core Viewpoint - The company Fosun Pharma plans to spin off its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange to enhance corporate governance and sustainable development, thereby maximizing shareholder value [1][4]. Company Summary - Fosun Antigen was established in July 2012 and focuses on the research, production, and sales of human vaccines, having developed platforms for both bacterial and viral vaccines [3]. - As of the announcement date, Fosun Pharma holds approximately 70.08% of Fosun Antigen's shares, while 17 other shareholders collectively own about 29.92% [3]. - Financial data indicates that Fosun Antigen achieved revenue of 97.42 million yuan in 2024, with a net loss of 123 million yuan. For the first half of 2025, revenue was 153 million yuan, with a net loss of 58.45 million yuan [3]. Industry Summary - The spin-off is expected to broaden financing channels and enhance market competitiveness for Fosun Antigen, while also allowing Fosun Pharma to deepen its presence in the vaccine sector [4]. - Fosun Pharma reported a revenue of 29.393 billion yuan for the first three quarters of 2025, a decrease of 4.91% year-on-year, while net profit increased by 25.5% to 2.523 billion yuan [4]. - The decrease in revenue is attributed to the impact of centralized drug procurement policies, although revenue from innovative drugs showed steady growth [4]. - The company is focusing on lean operations, cost reduction, and asset lightening to optimize its financial structure and maintain healthy cash flow [5]. - Other pharmaceutical companies, such as Dongcheng Pharmaceutical, are also planning to list subsidiaries on the Hong Kong Stock Exchange, indicating a trend among biopharmaceutical firms seeking international financing opportunities [6].